EPZM Epizyme, Inc.

+3  (17%)
Previous Close 14.90
Open 15.25
Price To book 4.29
Market Cap 1.02B
Shares 58,248,000
Volume 1,071,482
Short Ratio 8.48
Av. Daily Volume 441,171

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 interim data due at ASCO 2017 - June 4, 2017. Abstract 11057.
Solid tumors - cancer
Phase 2 dosing commenced August 2016. Enrollment to be completed in 2017.
Adult patients with mesothelioma characterized by BAP1 loss-of-function
Phase 2 futility analysis completed September 6, 2016. Futher data due at The International Conference on Malignant Lymphoma (ICML) - June 14, 2017.
Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma

Latest News

  1. Epizyme, Inc. breached its 50 day moving average in a Bullish Manner : EPZM-US : April 26, 2017
  2. Why Epizyme Inc. Shares Are Soaring Today
  3. Epizyme Announces Tazemetostat Fast Track Designation for Follicular Lymphoma and Plenary Session on Phase 2 NHL Data at ICML
  4. Epizyme Announces Date of First Quarter 2017 Financial Results and Tazemetostat Data Presentations at ASCO
  5. Why Is Epizyme (EPZM) Down 3.6% Since the Last Earnings Report?
  6. ETFs with exposure to Epizyme, Inc. : April 7, 2017
  7. Epizyme to Present New Preclinical Data on Tazemetostat and Epigenetic Target Identification Efforts at AACR Annual Meeting
  8. Epizyme, Inc. :EPZM-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  9. Epizyme, Inc. :EPZM-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017
  10. Epizyme (EPZM) Reports Narrower Q4 Loss, Pipeline in Focus
  11. Edited Transcript of EPZM earnings conference call or presentation 9-Mar-17 1:30pm GMT
  12. Epizyme (EPZM) Reports A Narrower Q4 Loss
  13. Epizyme reports 4Q loss
  14. Epizyme Reports 2016 Financial Results and Provides 2017 Pipeline Goals
  15. Epizyme President of Research and Chief Scientific Officer, Robert Copeland, Announces Retirement from the Company
  16. Can Epizyme (EPZM) Spring a Surprise This Earnings Season?
  17. Epizyme Announces 2016 Fourth Quarter and Full-Year Results Conference Call Date and March Investor Conferences
  18. Epizyme Elects Kevin Conroy to its Board of Directors
  19. Epizyme to Present at Upcoming Investor Conferences